Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception.

Background: Individualization of controlled ovarian stimulation (COS) for assisted conception is complicated by variable ovarian response to follicle stimulating hormone. We hypothesized that anti-Müllerian hormone (AMH), a predictor of oocyte yield, may facilitate treatment strategies for women undergoing COS, to optimize safety and clinical pregnancy rates.

Methods: Prospective cohort study of 538 patients in two centres with differential COS strategies based on a centralized AMH measurement.